Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

Background: Psychedelic drugs have shown an efficacy in some psychiatric disorders and
have an original mechanism of action with a 5-HT2A agonism. Aim: The aim of this meta …

Background Depression and anxiety are prevalent psychiatric disorders that carry significant
morbidity. Pharmacological and psychosocial interventions are used to manage these …

Background: Classical psychedelics are a group of drugs which act as agonists on the
serotonin-2A (5-HT2A) receptor. Evidence suggests they may have a uniquely rapid and …

Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have
been used and extensively studied in Western medicine as part of substance-assisted …

Objective Serotonergic psychedelics are re-emerging as potential novel treatments for
several psychiatric disorders including major depressive disorder. The Canadian Network …

Research on psychedelics has seen a recent revival, with many clinical trials focused on
their therapeutic potential to treat a range of mental health conditions. The purpose of this …

Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies
assessing the therapeutic effects of serotonergic psychedelics drugs for mental health …

Context People affected by serious illness usually experience suffering in its various
dimensions, not only in the physical but also in the psychosocial and spiritual aspects. The …